Caligan Partners LP
Caligan Partners LP reported 28 holdings worth US$2.13B as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Caligan Partners LP reported 28 holdings worth US$2.13B as of Jun 30, 2026. Largest: Liquidia Corporation, Revolution Medicines, Inc. and Abivax Sa. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 28
- Value as reported
- US$2.13B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Liquidia Corporation | 8.12M | US$647M | 30.5% |
| Revolution Medicines, Inc. | 1.96M | US$367M | 17.3% |
| Abivax Sa | 1.56M | US$208M | 9.8% |
| Vaxcyte, Inc. | 2.19M | US$127M | 6.0% |
| Exelixis, Inc. | 1.55M | US$84.5M | 4.0% |
| Tango Therapeutics, Inc. | 2.5M | US$78.2M | 3.7% |
| Avalo Therapeutics, Inc. | 3.16M | US$58.5M | 2.8% |
| Xenon Pharmaceuticals Inc. | 890K | US$53.7M | 2.5% |
| Adma Biologics Inc | 5.73M | US$47.9M | 2.3% |
| Lb Pharmaceuticals Inc | 1.44M | US$46.7M | 2.2% |
| Viridian Therapeutics, Inc. | 2.19M | US$40.3M | 1.9% |
| Vor Biopharma Inc. | 1.93M | US$35.4M | 1.7% |
| Sab Biotherapeutics, Inc. | 7.97M | US$31.1M | 1.5% |
| Inventiva Sa | 8.16M | US$30.9M | 1.5% |
| Aura Biosciences, Inc. | 4.3M | US$30.5M | 1.4% |
| Tyra Biosciences, Inc. | 807K | US$25.8M | 1.2% |
| Opus Genetics, Inc. | 6.08M | US$25M | 1.2% |
| Anika Therapeutics Inc. | 1.44M | US$21M | 0.99% |
| Sagimet Biosciences Inc. - Series A | 2.5M | US$19.3M | 0.91% |
| Artiva Biotherapeutics, Inc. | 1.74M | US$16.8M | 0.79% |
| Sensei Biotherapeutics, Inc. | 629K | US$15.7M | 0.74% |
| Mbx Biosciences, Inc. | 200K | US$11M | 0.52% |
| Verrica Pharmaceuticals Inc. | 924K | US$5.65M | 0.27% |
| Cellectar Biosciences, Inc. | 470K | US$1.31M | 0.06% |
| Xilio Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Maze Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Mineralys Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Spyre Therapeutics, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related